Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | POLA1 | P09884 | 2/20 | 0.41 |
| ▸ | POLD1 | P28340 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035069 | 0.85 | POLB (0.38) | POLBPOLA1POLD1P2RY2P2RY4 | |
| SCHEMBL2496583 | 0.85 | P2RY2 (0.53) | P2RY2P2RY4P2RY6 | |
| SCHEMBL3205916 | 0.84 | TYMS (0.43) | POLBPOLA1POLD1 | |
| SCHEMBL12768232 | 0.81 | TK1 (0.36) | — | |
| SCHEMBL12768231 | 0.81 | LMNA (0.43) | — | |
| SCHEMBL18589104 | 0.77 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL3345547 | 0.77 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL1032736 | 0.77 | TYMP (0.48) | — | |
| SCHEMBL13970818 | 0.77 | POLB (0.59) | POLBPOLA1POLD1 | |
| SCHEMBL1332964 | 0.76 | POLG (0.51) | POLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275538-B1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | TAGCYX BIOTECHNOLOGIES (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-8426569-B2 | DNA capable of being amplified by PCR with high selectivity and high efficiency | RIKEN (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20110053782-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | RIKEN (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2275538-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | Riken (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053782-A1 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY | POLRMT, POLN, POLL | POLB 4/4885POLA1 21/4885POLD1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.